{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:04:50Z","timestamp":1784678690127,"version":"3.55.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,21]]},"DOI":"10.7759\/cureus.113122","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:41:27Z","timestamp":1784677287000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced Metastatic Melanoma With C-KIT (CD117) Immunohistochemical Expression: A Case Report and Therapeutic Considerations"],"prefix":"10.7759","author":[{"given":"Patricia","family":"Flores Troche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Circe K.","family":"Ruiz Palafox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn Zadkiel","family":"Cruz Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Dzoara","family":"Fuentes-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Estefan\u00eda","family":"Mej\u00eda Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Mej\u00eda Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena Gintare","family":"Alvarez Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter SM","year":"2024","unstructured":"Swetter SM, Johnson D, Albertini MR, et al.. NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2024. J Natl Compr Canc Netw. 2024, 22:290-8. 10.6004\/jnccn.2024.0036","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: biological insights and clinical implications","volume":"61","author":"Pham DD","year":"2020","unstructured":"Pham DD, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020, 61:562-71. 10.3349\/ymj.2020.61.7.562","journal-title":"Yonsei Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0872","article-title":"KIT mutations in melanoma: clinical implications","volume":"27","author":"Shoushtari AN","year":"2021","unstructured":"Shoushtari AN, Carvajal RD. KIT mutations in melanoma: clinical implications. Clin Cancer Res. 2021, 27:4666-72. 10.1158\/1078-0432.CCR-21-0872","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2011.e20","article-title":"The usefulness of c-KIT in the immunohistochemical assessment of melanocytic lesions","volume":"55","author":"Pilloni L","year":"2011","unstructured":"Pilloni L, Bianco P, Difelice E, et al.. The usefulness of c-KIT in the immunohistochemical assessment of melanocytic lesions. Eur J Histochem. 2011, 55:e20. 10.4081\/ejh.2011.e20","journal-title":"Eur J Histochem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald JE","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al.. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017, 67:472-92. 10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402144","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"391","author":"Wolchok JD","year":"2024","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al.. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024, 391:997-1008. 10.1056\/NEJMoa2402144","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al.. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022, 386:24-34. 10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney J","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, et al.. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022, 10:10.1136\/jitc-2022-005755","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491397-advanced-metastatic-melanoma-with-c-kit-cd117-immunohistochemical-expression-a-case-report-and-therapeutic-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:41:28Z","timestamp":1784677288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491397-advanced-metastatic-melanoma-with-c-kit-cd117-immunohistochemical-expression-a-case-report-and-therapeutic-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.113122","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}